Ionis Pharmaceuticals Stock Forecast, Price & News

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Ionis Pharmaceuticals?

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Ionis Pharmaceuticals.

How can I listen to Ionis Pharmaceuticals' earnings call?

Ionis Pharmaceuticals will be holding an earnings conference call on Wednesday, November 3rd at 11:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.01. The business had revenue of $126 million for the quarter, compared to analysts' expectations of $128.46 million. Ionis Pharmaceuticals had a negative net margin of 78.78% and a negative trailing twelve-month return on equity of 58.39%. The business's revenue was down 13.7% on a year-over-year basis. During the same period last year, the business earned ($0.18) earnings per share.
View Ionis Pharmaceuticals' earnings history.

How has Ionis Pharmaceuticals' stock price been impacted by Coronavirus?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IONS shares have decreased by 38.1% and is now trading at $30.44.
View which stocks have been most impacted by COVID-19.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals issued an update on its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600 M-, compared to the consensus revenue estimate of $618.55 million.

What price target have analysts set for IONS?

9 analysts have issued 12-month price objectives for Ionis Pharmaceuticals' stock. Their forecasts range from $31.00 to $86.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $52.19 in the next year. This suggests a possible upside of 71.4% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:

• Brett P. Monia, Chief Executive Officer & Director
• Joel Edwards, Vice President-Corporate & Commercial Operations
• Elizabeth L. Hougen, Chief Financial Officer & Executive VP-Finance
• C. Frank Bennett, Chief Scientific Officer & Executive VP
• Sanjay Bhanot, Chief Medical Officer

Who are some of Ionis Pharmaceuticals' key competitors?

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of IONS's competitors.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.38%), Baillie Gifford & Co. (0.21%), Sicart Associates LLC (0.21%), BLB&B Advisors LLC (0.11%), Private Advisor Group LLC (0.03%) and Gateway Investment Advisers LLC (0.03%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Sicart Associates LLC, Nisa Investment Advisors LLC, and BLB&B Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Private Advisor Group LLC, Virginia Retirement Systems ET AL, Bard Financial Services Inc., Assenagon Asset Management S.A., Kestra Advisory Services LLC, Koshinski Asset Management Inc., and Pinnacle Associates Ltd..
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $30.44.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $4.30 billion and generates $729 million in revenue each year. The company earns $-451.29 million in net income (profit) each year or ($3.23) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 757 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Where are Ionis Pharmaceuticals' headquarters?

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at (760) 931-9200 or via email at [email protected].